Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil
- PMID: 22418886
- DOI: 10.1055/s-0032-1306424
Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil
Abstract
Nonalcoholic fatty liver disease (NAFLD) is easily the most common cause of chronic liver disease in the United States (U.S.) as the hepatic manifestation of the metabolic syndrome. Although only 5 to 20% of patients with NAFLD are generally considered to meet criteria for nonalcoholic steatohepatitis (NASH), with its inherent risk for progression to cirrhosis, this still represents an alarmingly large number of individuals. The exponentially growing rates of hepatocellular carcinoma (HCC) in the U.S. may be partially attributable to increased numbers of NASH cirrhotics, although recent evidence has suggested that NAFLD may directly promote hepatic carcinogenesis independent of cirrhosis. This review focuses on HCC in noncirrhotic NASH with an emphasis on clinical presentation, pathogenesis, and implications for screening.
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Similar articles
-
NAFLD leads to liver cancer: do we have sufficient evidence?Cancer Lett. 2014 Apr 10;345(2):230-4. doi: 10.1016/j.canlet.2013.07.033. Epub 2013 Aug 11. Cancer Lett. 2014. PMID: 23941829 Review.
-
Iron overload in nonalcoholic steatohepatitis.Adv Clin Chem. 2011;55:105-32. doi: 10.1016/b978-0-12-387042-1.00006-x. Adv Clin Chem. 2011. PMID: 22126026 Review.
-
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.Clin Liver Dis. 2018 Feb;22(1):201-211. doi: 10.1016/j.cld.2017.08.014. Clin Liver Dis. 2018. PMID: 29128057 Review.
-
Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.Can J Gastroenterol Hepatol. 2018 Aug 29;2018:8543763. doi: 10.1155/2018/8543763. eCollection 2018. Can J Gastroenterol Hepatol. 2018. PMID: 30228976 Free PMC article. Review.
-
Nonalcoholic fatty liver disease and hepatocellular carcinoma.Metabolism. 2016 Aug;65(8):1151-60. doi: 10.1016/j.metabol.2016.01.010. Epub 2016 Jan 23. Metabolism. 2016. PMID: 26907206 Review.
Cited by
-
New advances in drug development for metabolic dysfunction-associated diseases and alcohol-associated liver disease.Cell Biosci. 2024 Jul 6;14(1):90. doi: 10.1186/s13578-024-01267-9. Cell Biosci. 2024. PMID: 38971765 Free PMC article. Review.
-
Risk profile of hepatocellular carcinoma reveals dichotomy among US veterans.J Gastrointest Cancer. 2013 Sep;44(3):318-24. doi: 10.1007/s12029-013-9499-1. J Gastrointest Cancer. 2013. PMID: 23609167 Clinical Trial.
-
Mac-2 binding protein glycosylation isomer, the FIB-4 index, and a combination of the two as predictors of non-alcoholic steatohepatitis.PLoS One. 2022 Nov 10;17(11):e0277380. doi: 10.1371/journal.pone.0277380. eCollection 2022. PLoS One. 2022. PMID: 36355761 Free PMC article.
-
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103. World J Gastroenterol. 2015. PMID: 25892859 Free PMC article. Review.
-
Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma.Dig Dis Sci. 2015 Feb;60(2):420-6. doi: 10.1007/s10620-014-3364-3. Epub 2014 Nov 8. Dig Dis Sci. 2015. PMID: 25381201 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
